Pfizer has become the latest Big Pharma company to join a consortium that matches drugmakers to researchers in Cambridge, U.K.

Global pharma chief Hussain joins a long list of departing execs at GSK, Merrimack taps Sanofi Genzyme SVP Dr. Richard Peters as CEO, and ex-GSK rare disease…

An international team may have found an alternative approach to managing peripheral neuropathy that could potentially reverse symptoms with a class of drugs…

Immunomedics says new data for lead drug IMMU-132 in triple-negative breast cancer keep it on course to file for accelerated approval in mid-2017.

The UK BIA has responded with cautious optimism and concerns to the British prime minister’s clearest statement yet on the priorities for Brexit negotiations.

Carlo Russo has joined a growing list of ex-GlaxoSmithKline staffers moving into biotech after working on and helping launch the Big Pharma’s rare disease drug…

Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO.

Johns Hopkins researchers have landed on a synthetic peptide with effects lasting twice as long as the standard drug's, representing a potential…

Biogen is joining forces with Siemens Healthineers to develop MRI applications to quantify “key markers” indicating multiple sclerosis activity and progression.